Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b

Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies

“…We observed a downregulation of miR-26b in HCV-associated NHL tissues [16], and we showed the same pattern in PBMCs isolated from this category of patients [19,22]. Here we have confirmed previous results in a wider cohort of lymphoma patients, and, as explained above, driven by unexpected results in a small HCC group chosen as control, we tested a group of 25 patients with hepatic cancer and found statistically significant miR-26b downregulation.…”

“…Several studies have confirmed the involvement of cancer-related and newly identified miRNAs, namely miR-155, miR-146a, miR-21 and miR-26b, in the pathogenesis of different subtypes of lymphomas including some HCV-related ones (marginal zone lymphoma, MZL and diffuse large B cell lymphoma, DLBCL) [16][17][18][19]. MiR-21 and miR-26b have also been associated with the development of HCC and poor outcome after liver cancer therapy, respectively [20,21].…”

B cell non-Hodgkin’s lymphoma in chronic hepatitis C virus patients: An interesting relationship

“…One of the most obvious explanations, the genetic factor, has only recently been seriously reflected when the impact of this disease on chronic HCV infection and its role in predisposing to lymphoid malignancies has been recognized. Since then, some studies have tried to clarify the complex pathogenesis of MC [29] and the most recent have focused on genetics [33][34][35]. A French study stated that BLyS is strongly correlated with B cell proliferation during chronic HCV infection, and it has a strong role in the induction of mixed cryoglobulinemia and other HCV-associated BCP diseases, i.e.…”

The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis

“…The putative targets and functional effectors of miR-26b are the lymphoid enhancer binding factor 1 (LEF1) [80], overexpressed in chronic lymphocytic leukemia and in the monoclonal B cells lymphocytosis, a pre-lymphomatous condition [81], and cyclooxygenase-2, COX2 [79]. In this scenario, the downregulation of miR-26b associated with CV and NHL in HCV-positive patients, could be an indicator of a molecular mechanism of tumor progression [82].…”